128 related articles for article (PubMed ID: 29911373)
1. [Research progress of human cytochrome P450 2J2 and its ligands].
Ma HY; Ning J; Ge GB; Yang L; Hao DC
Yao Xue Xue Bao; 2017 Jan; 52(1):26-33. PubMed ID: 29911373
[TBL] [Abstract][Full Text] [Related]
2. Danazol Inhibits Cytochrome P450 2J2 Activity in a Substrate-independent Manner.
Lee E; Wu Z; Shon JC; Liu KH
Drug Metab Dispos; 2015 Aug; 43(8):1250-3. PubMed ID: 26048912
[TBL] [Abstract][Full Text] [Related]
3. Atypical kinetics of cytochrome P450 2J2: Epoxidation of arachidonic acid and reversible inhibition by xenobiotic inhibitors.
Leow JWH; Verma RK; Lim ABH; Fan H; Chan ECY
Eur J Pharm Sci; 2021 Sep; 164():105889. PubMed ID: 34044117
[TBL] [Abstract][Full Text] [Related]
4. Molecular determinant of substrate binding and specificity of cytochrome P450 2J2.
Xu L; Chen LY
Sci Rep; 2020 Dec; 10(1):22267. PubMed ID: 33335233
[TBL] [Abstract][Full Text] [Related]
5. Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
Lee CA; Jones JP; Katayama J; Kaspera R; Jiang Y; Freiwald S; Smith E; Walker GS; Totah RA
Drug Metab Dispos; 2012 May; 40(5):943-51. PubMed ID: 22328583
[TBL] [Abstract][Full Text] [Related]
6. Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes.
Evangelista EA; Kaspera R; Mokadam NA; Jones JP; Totah RA
Drug Metab Dispos; 2013 Dec; 41(12):2087-94. PubMed ID: 24021950
[TBL] [Abstract][Full Text] [Related]
7. Plant natural product plumbagin presents potent inhibitory effect on human cytochrome P450 2J2 enzyme.
Lu J; Liu D; Zhou X; Chen A; Jiang Z; Ye X; Liu M; Wang X
Phytomedicine; 2018 Jan; 39():137-145. PubMed ID: 29433675
[TBL] [Abstract][Full Text] [Related]
8. Terfenadone is a strong inhibitor of CYP2J2 present in the human liver and intestinal microsomes.
Lee E; Kim JH; Shon JC; Wu Z; Kim HJ; Gim M; Lee T; Liu KH
Drug Metab Pharmacokinet; 2018 Jun; 33(3):159-163. PubMed ID: 29759885
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Cytochrome P450 2J2-Mediated Metabolism of Rivaroxaban and Arachidonic Acid by Ibrutinib and Osimertinib.
Wang Z; Yong Chan EC
Drug Metab Dispos; 2022 Oct; 50(10):1332-1341. PubMed ID: 35817438
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 2J2: distribution, function, regulation, genetic polymorphisms and clinical significance.
Xu M; Ju W; Hao H; Wang G; Li P
Drug Metab Rev; 2013 Aug; 45(3):311-52. PubMed ID: 23865864
[TBL] [Abstract][Full Text] [Related]
11. LKY-047: First Selective Inhibitor of Cytochrome P450 2J2.
Phuc NM; Wu Z; O Y; Lee JH; Oh S; Song GY; Liu KH
Drug Metab Dispos; 2017 Jul; 45(7):765-769. PubMed ID: 28461575
[TBL] [Abstract][Full Text] [Related]
12. Inhibition and inactivation of human CYP2J2: Implications in cardiac pathophysiology and opportunities in cancer therapy.
Karkhanis A; Hong Y; Chan ECY
Biochem Pharmacol; 2017 Jul; 135():12-21. PubMed ID: 28237650
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 2J2: Potential Role in Drug Metabolism and Cardiotoxicity.
Solanki M; Pointon A; Jones B; Herbert K
Drug Metab Dispos; 2018 Aug; 46(8):1053-1065. PubMed ID: 29695613
[TBL] [Abstract][Full Text] [Related]
14. Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole.
Matsumoto S; Hirama T; Matsubara T; Nagata K; Yamazoe Y
Drug Metab Dispos; 2002 Nov; 30(11):1240-5. PubMed ID: 12386130
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth.
Chen C; Wei X; Rao X; Wu J; Yang S; Chen F; Ma D; Zhou J; Dackor RT; Zeldin DC; Wang DW
J Pharmacol Exp Ther; 2011 Feb; 336(2):344-55. PubMed ID: 21030485
[TBL] [Abstract][Full Text] [Related]
16. CYP2J2-mediated metabolism of arachidonic acid in heart: A review of its kinetics, inhibition and role in heart rhythm control.
Leow JWH; Chan ECY
Pharmacol Ther; 2024 Jun; 258():108637. PubMed ID: 38521247
[TBL] [Abstract][Full Text] [Related]
17. Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2.
Lafite P; Dijols S; Zeldin DC; Dansette PM; Mansuy D
Arch Biochem Biophys; 2007 Aug; 464(2):155-68. PubMed ID: 17470359
[TBL] [Abstract][Full Text] [Related]
18. Investigating the relevance of CYP2J2 inhibition for drugs known to cause intermediate to high risk torsades de pointes.
Leow JWH; Gu Y; Chan ECY
Eur J Pharm Sci; 2023 Aug; 187():106475. PubMed ID: 37225005
[TBL] [Abstract][Full Text] [Related]
19. Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Ren S; Zeng J; Mei Y; Zhang JZ; Yan SF; Fei J; Chen L
Drug Metab Dispos; 2013 Jan; 41(1):60-71. PubMed ID: 23033255
[TBL] [Abstract][Full Text] [Related]
20. The inhibitory potential of Broussochalcone A for the human cytochrome P450 2J2 isoform and its anti-cancer effects via FOXO3 activation.
Park SH; Lee J; Shon JC; Phuc NM; Jee JG; Liu KH
Phytomedicine; 2018 Mar; 42():199-206. PubMed ID: 29655687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]